[go: up one dir, main page]

DK1586309T6 - Polymere indgivelsesformuleringer af leuprolid med forbedret virkning - Google Patents

Polymere indgivelsesformuleringer af leuprolid med forbedret virkning Download PDF

Info

Publication number
DK1586309T6
DK1586309T6 DK05010806.7T DK05010806T DK1586309T6 DK 1586309 T6 DK1586309 T6 DK 1586309T6 DK 05010806 T DK05010806 T DK 05010806T DK 1586309 T6 DK1586309 T6 DK 1586309T6
Authority
DK
Denmark
Prior art keywords
present
directed
patient
flowable composition
implant
Prior art date
Application number
DK05010806.7T
Other languages
English (en)
Other versions
DK1586309T3 (da
Inventor
Richard L Dunn
John S Garrett
Bhagya L Chandrashekar
Harish Ravivarapu
Original Assignee
Tolmar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27099398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1586309(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tolmar Therapeutics Inc filed Critical Tolmar Therapeutics Inc
Publication of DK1586309T3 publication Critical patent/DK1586309T3/da
Application granted granted Critical
Publication of DK1586309T6 publication Critical patent/DK1586309T6/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3205—Separate rigid or semi-rigid containers joined to each other at their external surfaces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
DK05010806.7T 2000-09-21 2001-09-21 Polymere indgivelsesformuleringer af leuprolid med forbedret virkning DK1586309T6 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66617400A 2000-09-21 2000-09-21
US09/711,758 US6565874B1 (en) 1998-10-28 2000-11-13 Polymeric delivery formulations of leuprolide with improved efficacy
EP01973341.9A EP1322286B3 (en) 2000-09-21 2001-09-21 Polymeric delivery formulations of leuprolide with improved efficacy

Publications (2)

Publication Number Publication Date
DK1586309T3 DK1586309T3 (da) 2010-06-14
DK1586309T6 true DK1586309T6 (da) 2019-10-07

Family

ID=27099398

Family Applications (3)

Application Number Title Priority Date Filing Date
DK05010806.7T DK1586309T6 (da) 2000-09-21 2001-09-21 Polymere indgivelsesformuleringer af leuprolid med forbedret virkning
DK09012462.9T DK2158900T3 (da) 2000-09-21 2001-09-21 Polymere indgivelsesformuleringer af leuprolid med forbedret virkning
DK01973341.9T DK1322286T6 (da) 2000-09-21 2001-09-21 Polymere afgivelsesformuleringer af leuprolid med forbedret virkningsfuldhed

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK09012462.9T DK2158900T3 (da) 2000-09-21 2001-09-21 Polymere indgivelsesformuleringer af leuprolid med forbedret virkning
DK01973341.9T DK1322286T6 (da) 2000-09-21 2001-09-21 Polymere afgivelsesformuleringer af leuprolid med forbedret virkningsfuldhed

Country Status (26)

Country Link
US (8) US6565874B1 (da)
EP (3) EP2158900B1 (da)
JP (4) JP2004510807A (da)
KR (1) KR100831113B1 (da)
CN (2) CN101669900B (da)
AT (2) ATE296088T3 (da)
AU (4) AU9293101A (da)
BR (1) BRPI0114069B8 (da)
CA (1) CA2436275C (da)
CY (3) CY1106045T1 (da)
CZ (1) CZ303134B6 (da)
DE (2) DE60141421D1 (da)
DK (3) DK1586309T6 (da)
ES (3) ES2404559T3 (da)
HU (1) HU228386B1 (da)
IL (2) IL155006A0 (da)
IS (1) IS6794A (da)
MX (1) MXPA03002552A (da)
NZ (1) NZ525210A (da)
PL (1) PL226346B1 (da)
PT (3) PT1322286E (da)
RU (1) RU2271826C2 (da)
SI (1) SI1322286T1 (da)
SK (1) SK287528B6 (da)
WO (1) WO2002030393A2 (da)
ZA (1) ZA200302944B (da)

Families Citing this family (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8226598B2 (en) * 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
PT1310517E (pt) * 2000-08-07 2006-05-31 Wako Pure Chem Ind Ltd Polimero de acido lactico e processo para a sua producao
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
JP2004535431A (ja) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
AR034641A1 (es) 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
CN1485072A (zh) * 2002-09-28 2004-03-31 治疗前列腺疾病的薏苡仁油软胶囊及其应用
EP1622540A4 (en) * 2003-03-11 2009-12-30 Qlt Usa Inc PREPARATIONS OF ANTI-CANCER AGENTS DEPENDENT ON THE CELLULAR PROGRAM
DK1603532T3 (da) * 2003-03-14 2008-12-08 Debio Rech Pharma Sa Subkutant afgivelsessystem, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af cholinerge mangellidelser
CN1780555A (zh) * 2003-05-01 2006-05-31 韦斯特制药服务药物输送和临床研究中心有限公司 Lh－rh类似物亮丙瑞林的鼻部给药
US20040224000A1 (en) * 2003-05-05 2004-11-11 Romano Deghenghi Implants for non-radioactive brachytherapy of hormonal-insensitive cancers
WO2004103342A2 (en) * 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
ES2447423T3 (es) * 2003-08-29 2014-03-12 Dyax Corp. Inhibidores de proteasa poli-pegilados
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
CN1901931A (zh) * 2004-01-07 2007-01-24 特里梅里斯公司 HIV gp41 HR2－来源的合成肽,及其在抑制人类免疫缺陷性病毒传递的治疗中的用途
US20090023643A1 (en) * 2004-01-13 2009-01-22 Vasogenix Pharmaceuticals, Inc. Methods For Treating Acute Myocardial Infarction By Administering Calcitonin Gene Related Peptide And Compositions Containing The Same
CA2552757A1 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心脈管および腎臓の適応症のための制御放出ｃｇｒｐ送達組成物
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
CA2556923A1 (en) * 2004-02-20 2005-09-09 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
EP1729829A1 (en) * 2004-03-02 2006-12-13 Nanotherapeutics, Inc. Compositions for repairing bone and methods for preparing and using such compositions
TW200533385A (en) * 2004-03-03 2005-10-16 Commw Scient Ind Res Org Biocompatible polymer compositions for dual or multi staged curing
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
EP1773350B1 (en) 2004-07-12 2013-05-29 Allergan, Inc. Opthalmic compositions for treating ophthalmic conditions
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
AU2005316545A1 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
US20060189958A1 (en) * 2005-02-21 2006-08-24 Talton James D Inverted cannula for use in reconstituting dry material in syringes
EA200702434A1 (ru) * 2005-06-07 2008-06-30 Сэнт-Гобэн Керамикс & Пластикс, Инк. Носитель катализатора (варианты) и способ его получения
WO2007011340A1 (en) * 2005-07-14 2007-01-25 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
MX2008001638A (es) 2005-08-08 2009-02-24 Cytyc Corp Metodo de espaciado de piel entumecida.
GB0517673D0 (en) * 2005-08-31 2005-10-05 Astrazeneca Ab Formulation
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US20080103746A1 (en) * 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US20070142287A1 (en) * 2005-12-20 2007-06-21 Biomed Solutions, Llc Compositions And Methods For Treatment Of Cancer
WO2007082726A2 (de) * 2006-01-17 2007-07-26 Medigene Ag Fliessfähige leuprolid-haltige zusammensetzung zur behandlung von entzündungsvermittelten neurodegenerativen erkrankungen
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
JP4682251B2 (ja) 2006-02-02 2011-05-11 トリメリス，インコーポレーテッド 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド
US7935342B2 (en) * 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
US20070248611A1 (en) * 2006-02-02 2007-10-25 Pfizer Inc Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist
WO2007103346A2 (en) 2006-03-08 2007-09-13 The University Of North Carolina At Chapel Hill Polyester based degradable composition and implantable biomedical articles
ES2531679T3 (es) 2006-07-11 2015-03-18 Foresee Pharmaceuticals, Inc. Composiciones para la administración de liberación controlada de péptidos
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
TWI397426B (zh) * 2006-11-09 2013-06-01 Alcon Res Ltd 包含水不溶性聚合基質之淚點栓塞物
MX2009004856A (es) * 2006-11-09 2009-06-05 Alcon Res Ltd Matriz polimerica insoluble en agua para suministro de farmaco.
AR064381A1 (es) 2006-12-18 2009-04-01 Takeda Pharmaceutical Composicion de liberacion sostenida y metodos para producirla
US20090112197A1 (en) 2007-10-30 2009-04-30 Searete Llc Devices configured to facilitate release of nitric oxide
US8221690B2 (en) * 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US7862598B2 (en) * 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8642093B2 (en) * 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20090110933A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices related to nitric oxide releasing materials
JP5342459B2 (ja) 2007-02-15 2013-11-13 トルマー セラピューティクス， インコーポレイテッド． 低バーストポリ−（ラクチド／グリコシド）およびポリマーを生成するための方法
WO2008124013A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
BRPI0811319A2 (pt) * 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
WO2009040073A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2201028A2 (en) * 2007-09-25 2010-06-30 Trimeris, Inc. Novel methods of synthesis for therapeutic antiviral peptides
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20090112193A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems and devices that utilize photolyzable nitric oxide donors
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8349262B2 (en) * 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US20090112055A1 (en) * 2007-10-30 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Sleeves configured to facilitate release of nitric oxide
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
ES2718612T3 (es) 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US8828354B2 (en) 2008-03-27 2014-09-09 Warsaw Orthopedic, Inc. Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US8722079B2 (en) * 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US20090264478A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Sulfasalazine formulations in a biodegradable polymer carrier
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US9132085B2 (en) 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8557273B2 (en) 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US9289409B2 (en) * 2008-04-18 2016-03-22 Warsaw Orthopedic, Inc. Sulindac formulations in a biodegradable material
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
CN102112107A (zh) * 2008-06-03 2011-06-29 托马医疗科技公司 具有改进的释放动力学特征的控制释放共聚物制剂
EP2293784B1 (en) * 2008-06-03 2016-04-13 Indivior UK Limited Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system
HRP20150350T1 (hr) * 2008-06-03 2015-05-08 Tolmar Therapeutics, Inc. Tekuä†i pripravak koji sadrži biokompatibilne pripravke oligomer-polimer
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US9492375B2 (en) 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
CN101653422B (zh) * 2008-08-20 2013-03-20 山东绿叶制药有限公司 利培酮缓释微球、其制备方法和用途
US20100098746A1 (en) * 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US9161903B2 (en) * 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
US8980317B2 (en) * 2008-12-23 2015-03-17 Warsaw Orthopedic, Inc. Methods and compositions for treating infections comprising a local anesthetic
US8469779B1 (en) 2009-01-02 2013-06-25 Lifecell Corporation Method for debristling animal skin
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8653029B2 (en) 2009-07-30 2014-02-18 Warsaw Orthopedic, Inc. Flowable paste and putty bone void filler
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
US8597192B2 (en) 2009-10-30 2013-12-03 Warsaw Orthopedic, Inc. Ultrasonic devices and methods to diagnose pain generators
US8475824B2 (en) * 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US8758791B2 (en) * 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
ES2390439B1 (es) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
HRP20211853T1 (hr) 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
DK2394664T3 (da) 2010-05-31 2016-09-12 Laboratorios Farmacéuticos Rovi S A Antipsykotisk injicerbar depotsammensætning
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
EP2585092A1 (en) * 2010-06-24 2013-05-01 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
US8246571B2 (en) 2010-08-24 2012-08-21 Warsaw Orthopedic, Inc. Drug storage and delivery device having a retaining member
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
WO2012075451A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Clonidine and gaba compounds in a biodegradable polymer carrier
WO2012075447A2 (en) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Compositions and methods for delivering clonidine and bupivacaine to a target tissue site
CN103491946B (zh) 2010-12-29 2016-08-10 美蒂森 可生物降解的药物释放组合物
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
US8637067B1 (en) 2011-03-10 2014-01-28 Lifecell Corporation Elastic tissue matrix derived hydrogel
WO2012142419A1 (en) 2011-04-14 2012-10-18 Lifecell Corporation Regenerative materials
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9132194B2 (en) 2011-07-12 2015-09-15 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive sheet containing a drug depot
US9205241B2 (en) 2011-07-12 2015-12-08 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive material
US9089523B2 (en) 2011-07-28 2015-07-28 Lifecell Corporation Natural tissue scaffolds as tissue fillers
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
BR112014014975B1 (pt) 2011-12-20 2019-06-25 Lifecell Corporation Produto de tecido, e método para produzir uma composição de tecido
WO2013096249A1 (en) 2011-12-20 2013-06-27 Lifecell Corporation Sheet tissue products
EP3461508A1 (en) 2012-01-24 2019-04-03 LifeCell Corporation Elongated tissue matrices
US9511018B2 (en) 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
EP2841116A1 (en) 2012-04-24 2015-03-04 Lifecell Corporation Flowable tissue matrices
US8735504B2 (en) 2012-05-02 2014-05-27 Warsaw Orthopedic, Inc. Methods for preparing polymers having low residual monomer content
BR112015000547B1 (pt) 2012-07-13 2020-11-10 Lifecell Corporation método para tratar tecido
ES2849440T3 (es) 2012-09-26 2021-08-18 Lifecell Corp Tejido adiposo procesado
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
CN108042849B (zh) 2013-02-06 2021-04-20 生命细胞公司 用于组织产物的局部改性的方法
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US20160106804A1 (en) 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
EP3331495B1 (en) * 2015-08-03 2020-11-04 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
JP6835841B2 (ja) 2015-11-16 2021-02-24 エボニック オペレーションズ ゲーエムベーハー 非核酸系逆転写酵素阻害剤とポリ（ラクチド−ｃｏ−グリコリド）とを含む注射液
EP3377041B1 (en) 2015-11-16 2023-10-25 MedinCell S.A. A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
AU2017274190A1 (en) 2016-06-03 2018-12-13 Lifecell Corporation Methods for localized modification of tissue products
USD802757S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
WO2018102700A1 (en) * 2016-12-01 2018-06-07 Pinscreen, Inc. Photorealistic facial texture inference using deep neural networks
WO2018118944A1 (en) 2016-12-22 2018-06-28 Lifecell Corporation Devices and methods for tissue cryomilling
WO2018144603A1 (en) 2017-01-31 2018-08-09 Veru Inc. COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GANADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
KR102412628B1 (ko) * 2017-08-28 2022-06-23 차의과학대학교 산학협력단 전기분무 기술을 이용한 루프롤라이드 함유 서방성 미립구의 제조방법
WO2019066199A1 (ko) * 2017-09-27 2019-04-04 주식회사 제이피바이오지 지속형 팔미트산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물
AU2018351051A1 (en) 2017-10-18 2020-03-19 Lifecell Corporation Adipose tissue products and methods of production
US11123375B2 (en) 2017-10-18 2021-09-21 Lifecell Corporation Methods of treating tissue voids following removal of implantable infusion ports using adipose tissue products
CN111225690A (zh) 2017-10-19 2020-06-02 生命细胞公司 可流动无细胞组织基质产品以及产生方法
US11246994B2 (en) 2017-10-19 2022-02-15 Lifecell Corporation Methods for introduction of flowable acellular tissue matrix products into a hand
GB2568526A (en) 2017-11-20 2019-05-22 Rebio Tech Oy Composition
KR102522654B1 (ko) * 2017-12-18 2023-04-17 포시 파마슈티컬스 컴퍼니 리미티드 선택된 방출 기간을 갖는 약제학적 조성물
KR20210013088A (ko) 2018-05-24 2021-02-03 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
BR112020023982A2 (pt) 2018-05-24 2021-02-23 Celanese Eva Performance Polymers Llc dispositivo implantável para liberação prolongada de um composto de fármaco macromolecular
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
WO2020065401A1 (en) * 2018-09-25 2020-04-02 Tolmar International, Ltd. Liquid polymer delivery system for extended administration of drugs
CN109498852B (zh) * 2018-12-29 2022-06-24 广州噢斯荣医药技术有限公司 治疗骨科疾病的生物降解材料及其应用
US20200330547A1 (en) * 2019-04-22 2020-10-22 Tolmar International Limited Method of Treating a Child with Central Precocious Puberty using an Extended Release Composition
CA3141456A1 (en) 2019-05-27 2020-12-03 Tolmar International Limited Leuprolide acetate compositions and methods of using the same to treat breast cancer
AU2020283895A1 (en) 2019-05-30 2022-01-06 Lifecell Corporation Biologic breast implant
CN111214643A (zh) * 2020-03-11 2020-06-02 苏州善湾生物医药科技有限公司 一种基于皮下凝胶缓释的奥曲肽组合物、制备方法及应用
BR112022025817A2 (pt) 2020-06-30 2023-01-10 Chong Kun Dang Pharmaceutical Corp Composição injetável que compreende análogo de gnrh
CA3197170A1 (en) 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
US11908233B2 (en) 2020-11-02 2024-02-20 Pinscreen, Inc. Normalization of facial images using deep neural networks
MX2023007367A (es) 2020-12-23 2023-09-07 Tolmar International Ltd Metodos y sistemas para conjuntos de valvulas de jeringa mezcladoras.
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
KR102386163B1 (ko) 2021-12-03 2022-04-14 (주)인벤티지랩 류프로라이드를 포함하는 마이크로 입자 및 이의 제조 방법
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector
KR20240079177A (ko) 2022-11-28 2024-06-04 동국제약 주식회사 인-시튜 임플란트를 형성할 수 있는 서방형 약학 조성물 및 이의 제조방법
WO2025008759A1 (en) * 2023-07-05 2025-01-09 Tolmar International Limited Polymeric leuprolide acetate formulations
WO2025124422A1 (zh) * 2023-12-13 2025-06-19 长春金赛药业有限责任公司 一种原位皮下植入的女性激素调节组合物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3284417A (en) * 1963-11-13 1966-11-08 Union Carbide Corp Process for the preparation of lactone polyesters
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US4040420A (en) * 1976-04-22 1977-08-09 General Dynamics Packaging and dispensing kit
US4137921A (en) * 1977-06-24 1979-02-06 Ethicon, Inc. Addition copolymers of lactide and glycolide and method of preparation
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JP2988633B2 (ja) 1990-03-16 1999-12-13 三和生薬株式会社 発毛・育毛剤
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
RU2084458C1 (ru) * 1993-05-27 1997-07-20 Институт высокомолекулярных соединений РАН Декапептид, обладающий противоопухолевой активностью
DK0754032T3 (da) 1994-04-08 2002-04-02 Atrix Lab Inc Flydende frigivelsessammensætninger
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747637A (en) * 1995-09-07 1998-05-05 Mitsui Toatsu Chemicals, Inc. Bioabsorbable polymer and process for preparing the same
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
PT1238659E (pt) * 1996-02-02 2005-01-31 Alza Corp Libertacao sustentada de um agente activo utilizando um sistema implantavel
IL130532A0 (en) * 1996-12-20 2000-06-01 Alza Corp Gel composition and methods
JPH10279499A (ja) * 1997-04-04 1998-10-20 Takeda Chem Ind Ltd 子宮粘膜適用製剤
US5912225A (en) * 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
KR100321854B1 (ko) * 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
CN1146613C (zh) 1999-09-10 2004-04-21 三井化学株式会社 可降解的聚氨酯树脂
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2005059003A1 (en) * 2003-12-15 2005-06-30 The Children's Hospital Of Philadelphia Novel polyesters

Also Published As

Publication number Publication date
ATE458469T3 (de) 2010-03-15
EP1322286A2 (en) 2003-07-02
EP1586309B1 (en) 2010-02-24
PL226346B1 (pl) 2017-07-31
US20150150937A1 (en) 2015-06-04
EP1322286B1 (en) 2005-05-25
CN1474685A (zh) 2004-02-11
PT1322286E (pt) 2005-08-31
ATE296088T3 (de) 2005-06-15
DE60111068T2 (de) 2006-01-26
EP2158900B1 (en) 2013-01-23
JP2014240439A (ja) 2014-12-25
ES2241876T7 (es) 2018-02-16
NZ525210A (en) 2004-10-29
US6565874B1 (en) 2003-05-20
DK1322286T6 (da) 2017-11-13
US20070104759A1 (en) 2007-05-10
PL361671A1 (en) 2004-10-04
JP6061823B2 (ja) 2017-01-18
CZ20031124A3 (cs) 2003-12-17
CY1106045T1 (el) 2011-04-06
WO2002030393A3 (en) 2002-06-27
CN101669900B (zh) 2013-07-24
DK1586309T3 (da) 2010-06-14
ES2241876T3 (es) 2005-11-01
BRPI0114069B8 (pt) 2021-05-25
WO2002030393A2 (en) 2002-04-18
US8486455B2 (en) 2013-07-16
US20030133964A1 (en) 2003-07-17
CA2436275A1 (en) 2002-04-18
IS6794A (is) 2003-04-23
ES2341777T7 (es) 2020-05-08
CY1110653T1 (el) 2015-06-10
AU9293101A (en) 2002-04-22
US9254307B2 (en) 2016-02-09
EP1586309B3 (en) 2019-09-18
SK287528B6 (sk) 2011-01-04
CY1113920T1 (el) 2016-07-27
RU2271826C2 (ru) 2006-03-20
DE60111068T3 (de) 2018-01-04
ES2404559T3 (es) 2013-05-28
EP1586309A1 (en) 2005-10-19
AU2010201645B2 (en) 2012-07-12
DE60141421D1 (de) 2010-04-08
IL155006A (en) 2007-06-03
PT1586309E (pt) 2010-05-28
EP2158900A1 (en) 2010-03-03
JP2012012418A (ja) 2012-01-19
MXPA03002552A (es) 2005-09-08
HK1141459A1 (en) 2010-11-12
HUP0302981A2 (hu) 2004-01-28
US20160106805A1 (en) 2016-04-21
AU2001292931B2 (en) 2006-08-24
JP2004510807A (ja) 2004-04-08
CN100536922C (zh) 2009-09-09
CN101669900A (zh) 2010-03-17
US20040229912A1 (en) 2004-11-18
SK5152003A3 (en) 2003-10-07
JP2013253101A (ja) 2013-12-19
US6773714B2 (en) 2004-08-10
AU2006241376A1 (en) 2006-12-14
JP6087886B2 (ja) 2017-03-01
AU2010201645A1 (en) 2010-05-20
US20100226954A1 (en) 2010-09-09
KR20030064401A (ko) 2003-07-31
BR0114069A (pt) 2004-02-10
CA2436275C (en) 2007-01-02
KR100831113B1 (ko) 2008-05-20
ES2341777T3 (es) 2010-06-28
DE60111068D1 (de) 2005-06-30
DK2158900T3 (da) 2013-02-18
AU2006241376B2 (en) 2010-02-04
SI1322286T1 (en) 2005-10-31
JP5969190B2 (ja) 2016-08-17
DK1322286T3 (da) 2005-08-01
CZ303134B6 (cs) 2012-04-25
US20100234305A1 (en) 2010-09-16
BRPI0114069B1 (pt) 2016-08-23
HUP0302981A3 (en) 2006-07-28
PT2158900E (pt) 2013-03-11
IL155006A0 (en) 2003-10-31
EP1322286B3 (en) 2017-08-16
HK1139596A1 (en) 2010-09-24
HU228386B1 (hu) 2013-03-28
ZA200302944B (en) 2004-08-24

Similar Documents

Publication Publication Date Title
DK2158900T3 (da) Polymere indgivelsesformuleringer af leuprolid med forbedret virkning
ATE209907T1 (de) Flüssige mittel zur wirkstoffabgabe
PT1315771E (pt) Material biologicamente activo
WO2002011696A3 (en) Active tissue augmentation materials and method
WO2004069335A8 (en) Magnetic implants to treat body tissue structures
WO2004081196A3 (en) Formulations for cell- schedule dependent anticancer agents
EP1056473B8 (en) Targeted delivery of biologically active media
WO2005025508A3 (en) Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
PT774964E (pt) Entrega local controlada de agentes quimioterapeuticos para tratamento de tumores solidos
WO2006023803A3 (en) Methods of administering microparticles combined with autologous body components
BRPI0117343B8 (pt) composição fluida para uso como um implante de liberação controlada, processo para formação da mesma, uso, kit e implante sólido
WO2021107752A1 (es) Tinta para tatuajes temporales y proceso para elaborarla
DeRoberts et al. Intense Pulsed Light Tattoo Removal in Conjunction with Imiquimod (Aldaraо): A Double-Blind, Randomized Controlled Study